Mingde Biotech
-
Mingde Biotech\’s profit in 2023 dropped 98.22% year-on-year. The market value has exceeded the net value, but it still does not repurchase but uses 4 billion for financial management.
For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Produced by: Sina Finance Listed Company Research Institute Author: Tianli On the evening of April 25, Mingde Biotech released its 2023 annual report. The report shows that the company achieved a total operating income of 750 million yuan last year, a year-on-year decrease of 92.88%; a net profit attributable to shareholders of listed companies of 74.9259 million yuan, a year-on-year decrease of 98.22%; and a net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses. The net profit was -124 million yuan, turning from a profit of 4.158 billion yuan in the same period of 2022 to a loss. Public information shows that Mingde Biotechnology is mainly engaged in the research and development, production, sales and service of in vitro diagnostic reagents and diagnostic instruments. Judging from the performance of previous years, Mingde Biotech\’s performance will reach a high point in recent years in 2022. Among them, operating income increased from 176…